CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 500 enrolled
Drug / intervention
Rifaximin +1 moredrug
Likely dose
Rifaximin 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02009618
NCT02009618N/ACompleted
CompareCT.gov

The Effects of Rifaximin Therapy in Patients Pre-Diagnosed With Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo Controlled Study

Bezmialem Vakif University·interventional·Posted Dec 12, 2013·Updated Dec 12, 2013

In Brief

A clinical study evaluating Rifaximin and placebo for IBS. Completed, enrolled 500 participants across 1 site.

Detailed Summary

To evaluate the efficacy of Rifaximin therapy started prior to completion of advanced examination procedure (before colonoscopy) of patients pre-diagnosed with irritable bowel syndrome, and implement it into clinical practice.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIBS
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 12, 2013
Enrollment StartJan 1, 2013
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.6 years ago

Interventions

Rifaximindrug

Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.

placebodrug